Trial Profile
A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Motor neuron disease
- Focus Therapeutic Use
- 01 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 01 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 18 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.